Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide is a small molecule that functions as an inhibitor of human Matrix Metalloproteinase 12 (MMP12). MMP12, also known as macrophage elastase, is an enzyme involved in the breakdown of extracellular matrix components, particularly elastin, and plays a role in tissue remodeling and inflammatory responses. By inhibiting MMP12 activity, this compound helps maintain the structural integrity of the extracellular matrix and reduces inflammation. It has been investigated in preclinical models for its potential therapeutic benefits in conditions such as chronic obstructive pulmonary disease (COPD), atherosclerosis, certain types of cancer, neurodegenerative diseases, and abdominal aortic aneurysms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide.